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Elizabeth J. Shpall,1 Catherine M. Bollard,2 Claudio Brunstein3INTRODUCTION
Umbilical cord blood (CB) is being used increas-
ingly as a source of hematopoietic support for patients
with high-risk hematologic diseases lacking a human
leukocyte antigen (HLA)-matched bone marrow do-
nor. The first successful CB transplant was performed
in 1989 by Dr. Gluckman and colleagues [1]. Since
then, more than 20,000 CB transplants (CBTs) have
been performed world-wide in pediatric and adult pa-
tients. The ethnic diversity, relative ease of collection,
and ready availability as cryopreserved units, as well as
tolerance of higher degrees of HLA disparity between
donor and recipient, are positive attributes of CBwhen
compared to bone marrow or mobilized peripheral
blood progenitor cells (PBPCs). There are major lim-
itations of CB, however, which include a low cell dose
with associated delays in engraftment, and profound
delays in immune reconstitution resulting in high rates
of infectious complications. Graft-versus-host disease
(GVHD) also remains a concern, particularly in adult
patients. This session will present novel therapeutic
strategies that are currently in the clinic, addressing
these critical issues of delayed engraftment and im-
mune reconstitution as well as GVHD, with the singu-
lar goal of improving the survival of CBT patients.IMPROVING ENGRAFTMENTAND HOMING
OF CORD BLOOD
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Several strategies for ex vivo expansion of CB have
been investigated in clinical trials. In static liquid expan-
sion systems, CD341 or CD1331 CB cells are cultured
with combinations of growth factors and other growth-
promoting compounds in various flasks and/or tissue
culture bags [2,3]. Our initial M.D. Anderson CB
expansion protocol (#02-407, IND#7166) involved
culture of CD1331 CB cells in Teflon bags for 14 days
with media containing 100 ng/mL stem cell factor
(SCF), granuloctye-colony stimulating factor (G-CSF),
and thrombopoietin (TPO) [4]. In this system, the
CD1331 CB cells are initially cultured in bags with 50
mL of media/growth factors for 7 days and then trans-
ferred to a bag with 800 mL of fresh media and growth
factors for another 7 days, at which time they are washed
and infused.With this strategy, our patients experienced
a modest improvement in engraftment of 20 days for
neutrophils and 65 days for platelets compared to our
results in recipients of double unmanipulated CB units
who engrafted neutrophils in 22 days and platelets in
100 days. However, we experienced a loss of .50% of
the CB CD341 cells following the CD133-selection
procedure, which stimulated us to investigate the
mesenchymal stem cell (MSC)-based coculture system,
where we could culture the entire CB unit without the
need for positive selection.Coculture of CB on Mesenchymal Stem Cells
The hematopoietic microenvironment is com-
posed of both hematopoietic and nonhematopoietic
components. The stem cell ‘‘niche’’ provides complex
molecular cues that direct hematopoiesis and are in
part responsible for the regulation of differentiation
and maturation of hematopoietic stem cells (HSCs).
We postulated that coculture of CB cells with MSCs
would provide an improved milieu that would allow
us to expand the entire CB mononuclear cell (MNC)
fraction with improved results compared to the liquid
culture system. In preclinical studies, CBMNC cocul-
tured with established MSCmonolayers in media with
a growth factor regimen containing stem cell factor
(SCF), G-CSFs, and TPO for a total of 14 days. On
day 7, the nonadherent cells were removed from the
coculture and subjected to a secondary expansion inS39
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The original adherent layer, which was then composed
ofMSCs and CB hematopoietic progenitors, was refed
with fresh medium containing the growth factors. Cul-
ture was then continued for an additional 7 days (total
14 days). With this strategy, Robinson et al. [5] re-
ported a 10- to 20-fold increase in total nucleated cells
(TNCs), 7- to 18-fold increase in committed progen-
itor cells (granulocyte-macrophage colony forming
cells [GM-CFC]), 2- to 5-fold increase in primitive
progenitor cells (high proliferative potential colony
forming cells, HPP-CFC), and a 16- to 37-fold in-
crease in CD341 cells.MSC-CB Expansion Clinical Trial
Based on the preclinical results described above,
a clinical trial was initiated at M.D. Anderson in the
double CBT setting where 1 unit was expanded on
MSCs, whereas the second unit was infused without
manipulation (Protocol #05-0781, IND#13,034). Ini-
tially, bone marrow from a family member (minimum
of 2/6 HLA match) was used as the source of MSCs.
Approximately 100 mL of marrow was aspirated and
confluent MSCs generated over approximately 21
days. The CB unit with the lower TNC dose was
thawed, washed, and divided into 10 equal fractions.
Each fraction was placed into 1 flask containing
.70% confluent MSCs and cultured in expansion me-
dium containing 100 ng/mL each of SCF, Flt3-ligand
(FLT3L), G-CSF, and TPO. Following incubation
for 7 days at 37C, the nonadherent cells were col-
lected from each flask. The content of a single flask
was then placed into a 1-liter Teflon-coated culture
bag (total of 10 bags) and cultured in 800 mL of media
with fresh growth factors for an additional 7 days (14
days total). On day 7, the flasks were also refed with
50 mL of media/growth factors and incubated for the
second week. On transplant day 0, the unmanipulated
CB unit was infused, followed by the expanded CB
cells pooled from the bags and the flasks, and washed
prior to infusion. In the second cohort of patients, an
off-the-shelf Stro11 MSC preparation first described
by Simmons and Torok-Storb [6] and provided by
Angioblast Ltd (New York) was used.With this proce-
dure, the 10 flasks with confluent MSC layers were
generated in 4 days rather than the 21 days required
for the family member-derived MSCs. Once the flasks
were ready, the CB expansion procedure was then per-
formed exactly as described above. The results with ei-
ther the family members or the Angioblast MSCs were
very similar, with a 12-fold expansion of TNCs and
12- to 40-fold expansion of CD341 CB cells [7]. At
transplant, the contribution of the unmanipulated
CB included 2.35  107 (range: 0.2-8.2) TNC/kg
and 0.95  105 (range: 0-4) CD341 cells/kg, whereas
the contribution of the expanded CB unit was5.8  107 (range: 0.3-14.4) TNC/kg and 8.7  105
(range: 0-93.4) CD341 cells/kg. These were higher
doses than we have ever infused into any of our adult
recipients of unmanipulated double CBT, or CB ex-
panded with our liquid culture system. As with the
family member–derived MSCs, the median time to
neutrophil engraftment (500/mL) was 15 days (range:
9-42), and platelet engraftment (.20,000/mL) was 38
days (range: 13-62) with 26 patients (81%) of patients
becoming platelet transfusion independent. On trans-
plant day121, the chimerism assays revealed that the
MSC-expanded unit contributed to engraftment with
a mean of 19% of the mononuclear cell, 16% of the
T cell, and 14% of the myeloid fractions because of
the expanded unit. Subsequently, hematopoiesis was
increasingly derived from the unexpanded unit with
long-term engraftment provided exclusively by the un-
expanded unit by 6 months posttransplant in the vast
majority of patients. Accrual to this trial continues.
Notch-Mediated Cord Blood Expansion
Similarly promising results with rapid neutrophil
and platelet engraftment have been reported byDelaney
et al. [8], who utilized an immobilized, engineered form
of the Notch ligand Delta1 with recombinant growth
factors (SCF, FL, IL-6, TPO, and IL-3) to stimulate
ex vivo CB expansion of 1 of the units in the double
CBT settingwhere the second unitwas notmanipulated
prior to infusion. Accrual to their trial continues.
Fucosylation of Cord Blood to Enhance Homing
to the Bone Marrow
Although cell dose is clearly a limiting factor in
CBT, CB-derived hematopoietic progenitor cells
also appear to have a deficit in homing and engraft-
ment. This homing defect of CB cells is likely the result
of decreased fucosylation of cell surface molecules that
bind to P- and E-selectins expressed by the marrow
vasculature [9]. Increasing the level of CB cell surface
fucosylation with the enzyme fucoysyltransferase-VI
(FT-VI) (American Stem Cell Inc., Helotex, TX) in
conjunction with GDP-fucose may correct this defi-
ciency and improve the rate and extent of CB cells
homing to bone marrow. To test this hypothesis, we
treated CB CD341 cells with FT-VI, washed and in-
fused them into sublethally irradiated (270 cGy), non-
obese diabetic/severe combined immunodeficiency
(NOD/SCID) IL-2Rgammanull (NSG) mice. The
mice were monitored longitudinally via retro-orbital
bleeding for the presence of human cells in the periph-
eral blood by flow cytometry using the human CD451
antibody. Analysis demonstrated that human engraft-
ment in mice receiving CB CD341 cells treated with
FT-VI was detected more rapidly (earlier) and at a sig-
nificantly higher levels (∼4-fold) than in recipients of
untreated counterparts [10]. These data suggest that
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prove the speed and magnitude of engraftment. The
persistence of engraftment over the longer term (.8
weeks, data not shown) suggests that fucosylation
does not negatively impact the long-term repopulating
capacity of the graft. Based on this murine data, an
exploratory clinical trial in CBT patients is being
developed in the double CBT setting where 1 of the
units will be fucosylated prior to infusion. Although
expanded CB has more endogenous fucosylation than
unmanipulated CB, it is still lower than that found
on bone marrow or PBPCs. Thus, ultimately, we
plan to combine the CB expansion and fucosylation
procedures in attempt to provide maximal improve-
ment in time to engraftment in CBT patients with
high risk hematologic diseases.VIRUS AND TUMOR-SPECIFIC CORD BLOOD
IMMUNE CELLS
Catherine Bollard, MD
Virus-Specific Cytotoxic T Lymphocytes
from Cord Blood
Because of the antigen-inexperienced nature of CB,
there is a higherpercentage of na€ıveTcells inCB than in
peripheral blood (PB). Memory T cells are critical in
non-T cell–depleted grafts because the virus-specific
memory T cells present in the grafts confer protection
against viral infections and reactivation. For this reason,
viral infections including cytomegalovirus (CMV),
Epstein-Barr virus (EBV), and adenovirus (Ad) are
particularly problematic in patients after cord blood
transplantation (CBT) and are associated with signifi-
cant morbidity and mortality. Although ganciclovir/
foscarnet may help prevent or treat CMV, and CD20-
specific antibodies may control EBV-associated lym-
phoproliferation, these drugs are expensive, toxic, and
often ineffective because of primary or secondary resis-
tance. InfectionswithAdarebeing reported increasingly
after CBT, and effective treatments are not currently
available. These deficiencies in conventional therapeu-
tics have increased interest in an immunotherapeutic
approach to viral disorders. Adoptive transfer of T cells
in the form of donor lymphocyte infusions (DLI) has
been used to treat viral infection after allogeneic hema-
topoietic stem cell transplantation (HSCT), but has so
far proved to be of limited effectiveness for patients
with viral infections such as Ad, and often produce
GVHD. Adoptive transfer of peripheral blood derived
virus-specific cytotoxic T lymphocytes (CTL) directed
toCMV, EBV, and Ad can rapidly reconstitute antiviral
immunity post-HSCTwithout causingGVHD[11-13].
We have shown that peripheral blood-derived T cell
lines enriched in cells recognizing CMV, EBV, and Ad
can reproducibly control infections by all 3 viruses afterallogeneic HSCT [13]. This study demonstrated that
the multivirus-specific T cells expand in vivo and are
active against all 3 viruses. Furthermore, by restoring
immunity to 3 viruses simultaneously, the need for con-
tinued prophylaxis with pharmacotherapy is eliminated,
thus improving the efficiency and cost effectiveness of
protecting HSCT recipients from these potentially
lethal viruses.
Inprinciple, this strategy couldbe appliedwith com-
parable success to recipients ofCB transplants; however,
certain obstacles to the extension of this approach must
be circumvented.These include: (1) the limitednumbers
of CB T cells available for manipulation and (2) the
na€ıvete of CB T cells [14]. Hence, the development of
virus-protective T cell therapy for patients undergoing
CBT requires the priming and extensive expansion of
na€ıve T cells rather than the more limited and simple
direct expansion of preexisting virus-specific memory
T cell populations from virus-experienced donors.
Further, CB T cells have lower cytotoxic activity and
higher activation-induced cell death than peripheral
bloodT cells.These limitations have prevented the pro-
duction of virus-specific CB-derived CTL in sufficient
numbers for clinical use. Because of these challenges,
only a few reports document the generation of
antigen-specific T cells from CB. Sun et al. [15] first
reported the ability to generate EBV-specific CD41
T cells using EBV-transformed B cells, or lymphoblas-
toid cell lines (LCL). Park et al. [16] then reported the
ability to generate CMV-pp65–specific T cells from
cord blood by using CMV-immune complex-loaded
DCs, CMV lysate, and IL-12 and IL-7. We have
now shown that Ad5f35pp65-transduced CB-derived
antigen-presenting cells (APC) can be used to generate
large numbers of autologous T cells specific for both
CMV and Ad, even from the phenotypically na€ıve
T cell subpopulation. Addition of EBV-transformed
B-lymphoblastoid cell lines (LCL) to the APCs allows
theAd/CMVspecificity of theCBTcells to be extended
to EBV. In addition, the multivirus-specific T cells rec-
ognize an array of epitopes after only 2 weeks expansion
in vivo.We therefore suggest that our ability to generate
virus-specific CTL from CB against a plethora of epi-
topes recognized by both CD41 and CD81 T cells
should minimize the risk of viral escape and maximize
therapeutic benefit on administration of these cells to
cord blood recipients at risk of severe viral disease [17].
A clinical trial using CB-derived multivirus-specific T
cells for the prevention and treatment of viral infection
after CBT is open and has started to accrue patients.
(Clinical Trial #: NCT01017705).Redirecting Specificity of CB-Derived T Cells to
Leukemia Antigens
Although the control of viral infectionsby infusionof
CB-derived multivirus-specific CTL would represent
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should be emphasized that at least 35% of patients
with B-ALL relapse after allogeneic HSCT or CBT
with\10%achieving long-term survival.Targetingma-
lignancies using exogenous receptors (often antibodies)
expressed on peripheral blood ex vivo–expanded T cells
(known as chimeric antigen receptors, or CARs) is an
evolving therapy for both hematologic malignancies
and solid tumors [18]. In recent years, this approach
has been translated to the cord blood setting by expand-
ing CB-derived T cells that are genetically modified to
express CD19 or CD20 CARs [19]. First-generation
CARs are most commonly composed of an antigen-
binding portion made of the variable domains of the
heavy and light chains of a mAb, linked as a single chain
Fv antibody (scFv). To this is coupled a signaling region
from either the z-chain of the TCR/CD3 complex, or
the g-chain of FceRI receptor. When expressed in T
cells, the CAR binds the antigen expressed on the cell
surfaceof the tumor target cells through its scFv endodo-
main and triggers T cell effector function through its
FcR-gamma or CD3-z endodomain. A major advantage
of CARs are their major histocompatibility complex
(MHC)-independent antigen recognition of native mol-
ecules rather than processed proteins. Several in vitro
and in vivo preclinical models have shown significant
antitumor effects using this strategy. B cell–derived ma-
lignancies are particularly well suited to targeting by
CAR-expressing T cells, because tumor cells almost
invariably express CD19, an antigen physiologically
expressed only by B lymphocytes and not by HSCs. T
lymphocytes expressing a transgenic CAR directed to
CD19 are highly effective at eliminatingCD191 tumors
in animal models [20], indicating that this strategy may
have clinical benefits. Expression of CARs by genetically
modifiedT cells provides themwith a novel tumor spec-
ificity, whereas the engagement of their native abTCRs
by (latent) viral antigens on APCs provides full costimu-
lation in vivo. This concept was demonstrated in vitro
and in animal models. Similar results were also repro-
ducedusingCTLsspecific forother viruses including in-
fluenza and varicella zoster. Importantly, this concept
was validated in patients with relapsed/refractory neuro-
blastomawho received both autologousEBV-CTLsand
activatedT cells (ATCs), each expressing a CAR, distin-
guishablebyquantitativePCR, that targeted theGD2 tu-
mor antigen, confirming that only the CAR-transduced
EBV-CTL persisted long term [21]. Recently,
Micklethwaite et al. [22] expanded the concept by trans-
ducing antigen-specific T cells derived from CB with
a (CAR) against the B cell malignancy marker CD19.
These cells coexpress endogenous TCRs for 3 of the
most common viruses that affect patients after CB trans-
plantation (CMV, EBV, and Ad) as well as the CAR
CD19. The adoptive transfer of multivirus-specific
CTL expressing CAR-CD19 therefore has the potentialto afford sustained protection against both malignant
relapse and lethal viral infections.
Cord Blood–Derived Natural Killer (NK) Cells
NK cells are innate immune cells that recognize
‘‘nonself’’ by the absence of Class I molecules and inhib-
itory receptors. Although the proportion of NK cells in
CB is similar to that of adult peripheral blood, the NK
cells found in CB are immature both in phenotype and
function. NK cells from CB have been reported to ex-
press less of the activation receptor NKG2C and more
of the inhibitory receptors NKG2A and KIRs. CB NK
cells also express less granzyme and hence are less cyto-
toxic than PB NK cells.
Because of the promise of allogeneic NK cell ther-
apy, several groups have developed methods to isolate
NK cells from peripheral blood of healthy donors, pri-
marily by leukopheresis and subsequent isolation by
magnetic beads [23]. However, 1 significant limitation
when using CB-derived products is the finite volume
of blood and cells from a CB unit. This limitation
has led to the development of methods to expand
NK cell numbers in vitro. One approach recently
described uses CD32/CD561 CB-derived cells ex-
panded in T-25 flasks in media containing human se-
rum and 500 U/mL IL-2. After expansion, the CB
NK cells had cytolytic function in vitro against acute
myelogenous leukemia (AML) blast targets. Further,
when these expanded CB NK cells were transferred
to a NOD-SCID-IL2Rgnull mouse model of human
AML, the NK cells exhibited in vivo antileukemic ac-
tivity, suggesting the potential of using donor-derived
CB NK cells to prevent relapse [24]. However,
whether ex vivo–expanded CB NK cells will be more
efficacious in this setting still remains to be tested.
Conclusion
In summary, despite the many advantages of utiliz-
ingCB as a source of allogeneic stem cells, utilizing CB
immune cells for clinical use is still in its infancy. The
use of CB-derived virus and leukemia-specific T cells
and NK cells still needs to be translated to the clinical
setting to enable researchers to evaluate and optimize
the successes and failures of these approaches. Never-
theless, these CB-derived immune-based therapies will
serve to address critical areas of CB transplantation
that have the potential to improve the outcomes of
CBT in patients.UMBILICAL CORD BLOOD–DERIVED
REGULATORY T CELLS
Claudio G. Brunstein, MD, PhD
GVHD is the culmination of a complex interplay of
donor and host factors that leads tomassive tissue injury
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of work, GVHD delays immune reconstitution and
therefore remains an important cause of morbidity
andmortality after allogeneic transplantation that limits
the success of this therapeutic approach. Immune re-
constitution is critical for full recovery after hematopoi-
etic cell transplantation (HCT) and is often delayed by
the development of acute GVHD [25]. Strategies to
reduce the risk of acute GVHD (aGVHD), and there-
fore improve immune reconstitution, have typically
met with variable success because of an increase in the
risk of relapse and/or opportunistic infections [26].
Regulatory TCells (Tregs)
Tregs are a subset of CD4
1 T cells that coexpress
CD25 (IL-2Ra chain). Tregs have been shown to be
critically involved with self-tolerance and the preven-
tion of autoimmunity. In mice, Tregs constitute
approximately 5% to 10% of lymph node (LN) or
spleen CD41 T cell populations. Tregs express high
levels of L-selectin (CD62L), preferentially migrate
to secondary lymphoid organs (the putative site of al-
logeneic priming and GVHD initiation) and markedly
impair the activation and expansion of alloreactive
CD41 and CD81 T cells and GVHD lethality [27].
CD62hi Tregs can inhibit host antidonor-mediated
graft rejection, resulting in high levels of chimerism
under conditions in which control mice fully rejected
the donor grafts. Importantly, Trenado et al. [28]
have shown that Treg infusions into allogeneic recipi-
ents suppress GVHD and support more rapid and
complete immune reconstitution than controls not
receiving Tregs. Despite the suppressive effect Tregs
exert on GVHD, graft-versus-leukemia (GVL) effects
in murine models of AML and lymphoid leukemia/
lymphoma are generally preserved [29].
Acute GVHD in Double Umbilical Cord Blood
Transplantation
Our group demonstrated the safety and efficacy
of coinfusing 2 partially HLA-matched CB units in
recipients of myeloablative and nonmyeloablative con-
ditioning regimens. Despite encouraging results, we
have also shown that the risk of grade II-IV acute
GVHD after double CB (DCB) is higher when com-
pared to recipients of single CB grafts (58% versus
39%, P \ .01) [30]. The increased risk of GVHD
was largely because of an increase on the incidence of
grade II skinGVHD. Inmultivariable analysis, the uti-
lization of DCB grafts was identified as independent
predictors of a higher risk of aGVHD. A recent study
showed that aGVHD is a frequent complication of
HSC with any donor type [31]. The incidence of
aGVHD in recipients of grafts from matched related
donors was 65% (95% confidence interval [CI],
57%-73%), matched unrelated donors 80% (95%CI, 70%-90%), mismatched unrelated donors 85%
(95% CI, 68%-100%), and DCB 60% (95% CI,
50%-70%). Although these data support DCB trans-
plantation as a valuable alternative hematopoietic
progenitor cell source for HCT, the need for pro-
longed immunosuppression delays the reconstitution
of T cell subsets, adversely impacts on the risk of op-
portunistic infections, metabolic complications, and
may adversely impact quality of life. Strategies to re-
duce the risk and severity of GVHD have most often
utilized pharmacologic immunosuppressants, such as
a calcineurin inhibitor, in combination with an antime-
tabolite, such as mycophenolate mofetil or methotrex-
ate. Alternatively, targeted elimination of the donor
T cell, the putative effector responsible for the patho-
genesis and pathology of the GVH reaction, has been
explored with variable success [26]. Thus, a novel strat-
egy, such as adoptive transfer of Treg, that can reduce
the risk of aGVHD without impacting the risk of re-
lapse and delay in immune reconstitution is potentially
be applicable to HSC transplantation in general.Adoptive Transfer of Ex Vivo–Expanded
Umbilical CB–Derived Tregs
Based on a series of murine experiments that
showed that the use of Tregs could suppress or treat
aGVHDwe developed a current GoodManufacturing
Practice (cGMP) methodology to ex vivo expand CB-
derived Tregs that consistently provided suppression in
allogeneic mixed lymphocyte reactions (with.97% of
lines providing .90% suppression at expansion rates
of 200-fold after 186 1 days in culture). We then con-
ducted the first-in-human dose escalation clinical trial
of CB Treg [32]. This was a single-center open-label,
dose escalation trial designed to assess the safety
profile and maximal tolerated dose (MTD) of ex
vivo–expanded/activated umbilical CB–derived Tregs.
Dose levels were 1, 3, 10, or 30  105 Treg/kg actual
body weight on day 11 (cells fresh out of expansion
culture) with an additional cohort who received a sec-
ond dose of 30  105 Treg/kg on day 115 (cryopre-
served cells derived from the same expansion culture)
after CBT. Dose escalation occurred after 1 patient re-
ceived the cells, unless a dose-limiting toxicity (DLT)
was observed or there was lack of sufficient expansion
of the Treg product to meet the planned dose. There
was no intrapatient dose escalation. CB units identified
for Treg manufacture contained a median of 16  108
total nucleated cells (range: 0.8-3.4) at the time of
thawing. Cell recoveries post-CD251 column selec-
tion showed 65% of the cells to be CD41/CD251,
and at the end of the ex vivo expansion process, 86%
were CD41/CD251, with a median of 86% suppres-
sion at 1:4 Treg/effector ratio. Because all prior CBT
experience at this institution incorporated cyclospor-
ine (CsA) immunoprophylaxis, the MTD was first
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As CsA has been shown to potentially interfere with
optimal Treg function and survival [33], the last cohort
received the maximal dose of Treg but in the presence
of MMF and sirolimus rather than CsA. In the 23 pa-
tients studied, we observed a transient increase in the
proportion of peripheral CD41 T cells that were
FoxP31CD1272 that was similar in recipients of
CsA and sirolimus. We also observed that the propor-
tion of these cells in the peripheral blood after the in-
fusion of the cryopreserved product infused on day
115 was lower when compared to freshly infused Tregs
on day11. Based on informative HLA markers on the
unit that generated the CB-Treg, we were able to dem-
onstrate circulating ex vivo–expanded Tregs in a patient
subgroup. In the doses tested, there was no DLT.
Moreover, incidences of grades III-IV aGVHD,
chronic GVHD (cGVHD), sustained donor engraft-
ment, and the probability of disease-free survival
(DFS) were similar between recipients of Tregs com-
pared to 108 similarly treated historic controls that
did not receive Tregs. However, there was statistically
significant decrease in the incidence of grade II-IV
aGVHD in Treg recipients was 43% (95% CI, 23%-
64%) compared to 61% (95% CI, 51%-72%) in 108
historic controls (P 5 .05). Notably, the incidence of
aGVHDwas also lower if we considered the subgroup
of 18 patients who received a Treg dose $30  105/kg
(39%, 95% CI, 16%-61%; P 5 .04).Conclusion
In summary, the safety of the administration of
CB-derived Treg up to a dose of 30  105/kg after
CBTwas demonstrated in this first study. Future stud-
ies will focus on characterizing the kinetics of ex vivo–
expanded CB-derived Tregs in the context of sirolimus
and mycophenolate mofetil and in the absence of
pharmacologic immunosuppression and further dose
escalation once novel, more efficient techniques to
expand CB-derived Treg are developed.ACKNOWLEDGMENTS
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